EMJ Oncology 12 [Supplement 1] . 2024

In this issue

This insightful article discusses the latest advancements in endometrial cancer research in 2023, including key data from renowned congresses throughout the year. The article highlights the unprecedented progression-free survival data from two Phase III randomised controlled trials evaluating first-line immunotherapy in combination with chemotherapy in patients with advanced or recurrent endometrial cancer: RUBY with dostarlimab, and NRG-GY018 with pembrolizumab, which created a buzz in March, and stimulated discussion throughout the remainder of the year. The overall survival results, clinically meaningful benefits regardless of mismatch repair status, and health-related quality of life in these studies are also discussed.